D-myo-inositol 1,4,5-trisphosphate (InsP) is a fundamental second messenger in cellular Ca mobilization. InsP 3-kinase, a highly specific enzyme binding InsP in just one mode, phosphorylates InsP specifically at its secondary 3-hydroxyl group to generate a tetrakisphosphate. Using a chemical biology approach with both synthetised and established ligands, combining synthesis, crystallography, computational docking, HPLC and fluorescence polarization binding assays using fluorescently-tagged InsP, we have surveyed the limits of InsP 3-kinase ligand specificity and uncovered surprisingly unforeseen biosynthetic capacity. Structurally-modified ligands exploit active site plasticity generating a helix-tilt. These facilitated uncovering of unexpected substrates phosphorylated at a surrogate extended primary hydroxyl at the inositol pseudo 3-position, applicable even to carbohydrate-based substrates. Crystallization experiments designed to allow reactions to proceed in situ facilitated unequivocal characterization of the atypical tetrakisphosphate products. In summary, we define features of InsP 3-kinase plasticity and substrate tolerance that may be more widely exploitable.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10876669 | PMC |
http://dx.doi.org/10.1038/s41467-024-45917-5 | DOI Listing |
BMC Genomics
April 2024
School of Life and Health Science, Huzhou College, Huzhou, Zhejiang, China.
Background: In Eukaryotes, inositol polyphosphates (InsPs) represent a large family of secondary messengers and play crucial roes in various cellular processes. InsPs are synthesized through a series of pohophorylation reactions catalyzed by various InsP kinases in a sequential manner. Inositol 1,4,5-trisphosphate 3-kinase (IP3 3-kinase/IP3K), one member of InsP kinase, plays important regulation roles in InsPs metabolism by specifically phosphorylating inositol 1,4,5-trisphosphate (IP3) to inositol 1,3,4,5-tetrakisphosphate (IP4) in animal cells.
View Article and Find Full Text PDFSignal Transduct Target Ther
March 2024
Xiangya Cancer Center, Xiangya Hospital, Central South University, Changsha, 410008, China.
Temozolomide (TMZ) represents a standard-of-care chemotherapeutic agent in glioblastoma (GBM). However, the development of drug resistance constitutes a significant hurdle in the treatment of malignant glioma. Although specific innovative approaches, such as immunotherapy, have shown favorable clinical outcomes, the inherent invasiveness of most gliomas continues to make them challenging to treat.
View Article and Find Full Text PDFRes Pract Thromb Haemost
January 2024
School of Cardiovascular and Metabolic Medicine and Sciences, BHF Centre for Research Excellence, London, UK.
Background: Inositol 1,3,4,5-tetrakisphosphate (IP) is formed from inositol 1,4,5-trisphosphate (IP) by IP 3-kinase (ITPK) in most cells. Its function is unknown but has been suggested to be involved in Ca entry, IP regulation, and phosphoinositide 3-kinase antagonism.
Objectives: To better elucidate a function for IP, we tested a specific inhibitor of ITPK (GNF362) on platelets, the effects of IP directly in permeabilized platelets and its effect on phosphatidylinositol 3,4,5-trisphosphate (PIP) binding to pleckstrin-homology (PH) domain-containing proteins in platelets.
Nat Commun
February 2024
Department of Crystallography and Structural Biology, Institute of Physical-Chemistry Blas Cabrera, CSIC, Serrano 119, 28006, Madrid, Spain.
D-myo-inositol 1,4,5-trisphosphate (InsP) is a fundamental second messenger in cellular Ca mobilization. InsP 3-kinase, a highly specific enzyme binding InsP in just one mode, phosphorylates InsP specifically at its secondary 3-hydroxyl group to generate a tetrakisphosphate. Using a chemical biology approach with both synthetised and established ligands, combining synthesis, crystallography, computational docking, HPLC and fluorescence polarization binding assays using fluorescently-tagged InsP, we have surveyed the limits of InsP 3-kinase ligand specificity and uncovered surprisingly unforeseen biosynthetic capacity.
View Article and Find Full Text PDFBiosci Rep
September 2023
Department of Pathology, University of California Irvine Medical Center, Orange, CA 92868, U.S.A.
1,4,5-triphosphate 3-kinase A (ITPKA) was first described and characterized by Irvine et al. in 1986 and cloned by Takazawa et al. in 1990.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!